State Sens. Doug Steinhardt (R-Lopatcong) and Vin Gopal (D-Long Branch) are teaming up on a bipartisan package to lower prescription drug costs by reining in pharmacy benefit managers.
The two senators announced the introduction of S-4692 and S-4693 today, arguing that pharmacy benefit managers, known as PBMs, have gained too much control over prescription drug prices and where patients fill their prescriptions.
PBMs serve as intermediaries among health insurers, drug manufacturers and pharmacies, negotiating prices and determining which medications insurance plans cover.
Steinhardt has made PBM reform a focus in recent months, including a series of op-eds published by the New Jersey Globe. He and Gopal jointly authored the most recent installment.
“The cost of most goods are influenced by supply and demand, but prescription drug costs are manipulated by shady middlemen known as PBMs,” Steinhardt said.
Steinhardt said the industry’s increasing vertical integration lets PBMs operate as insurers, pharmacy operators, and prescription drug middlemen, creating conflicts of interest when they steer patients toward businesses they control.
“My bill package puts patients ahead of the PBM business model and demands greater fairness, transparency, and accountability from the prescription drug market,” he said.
Gopal said the legislation is intended to protect both consumers and local pharmacies.
“New Jersey families should not have to pay more for the medications they rely on because of a system that lacks transparency and accountability,” Gopal said. “I’m proud to work across the aisle on commonsense solutions that will help lower costs, protect patients and local pharmacies, and bring greater accountability to PBMs.”



